Terumo (OTCMKTS:TRUMY) Posts Earnings Results, Misses Expectations By $0.01 EPS

Terumo (OTCMKTS:TRUMY) posted its earnings results on Friday. The company reported $0.14 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01), reports. The firm had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.82 billion. Terumo had a return on equity of 9.39% and a net margin of 12.35%.

Terumo Stock Up 6.1%

OTCMKTS:TRUMY traded up $0.81 on Friday, reaching $14.15. The stock had a trading volume of 118,616 shares, compared to its average volume of 427,611. The company has a 50-day moving average of $14.15 and a 200 day moving average of $15.92. The company has a current ratio of 2.51, a quick ratio of 1.46 and a debt-to-equity ratio of 0.07. The stock has a market cap of $20.87 billion, a P/E ratio of 23.58 and a beta of 0.74. Terumo has a 12-month low of $12.51 and a 12-month high of $20.12.

About Terumo

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.